Recent advances in psoriasis: Bench to bedside

Rett syndrome from bench to bedside: recent advances

Advances in Neuroimmunology: From Bench to Bedside

1 Department of Translational Medicine, Section of Neurology, University of Eastern Piedmont Amedeo Avogadro, 28100 Novara, Italy 2 Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont Amedeo Avogadro, 28100 Novara, Italy 3 Department of Neurorehabilitation and INSPE, San Raffaele Scientific Institute, 20132 Milan, Italy 4Department of Neurology, Oakl...

Recent advances in the management of mucormycosis: from bench to bedside.

Recent therapeutic advances have the potential to improve outcomes of mucormycosis. Lipid formulations of amphotericin B (LFAB) have evolved as the cornerstone of primary therapy for mucormycosis. Posaconazole may be useful as salvage therapy, but it cannot be recommended as primary therapy for mucormycosis on the basis of available data. Preclinical and limited retrospective clinical data sugg...

Research advances in esophageal diseases: bench to bedside

Over the last year, significant steps have been made toward understanding the pathogenesis of esophageal diseases and translating this knowledge to clinical practice. Gastroesophageal reflux disease (GERD) is the most common outpatient diagnosis in gastroenterology and has a high prevalence in the general population. As many as 40% of patients with GERD have incomplete response to medical thera...

Advances in knowledge on microscopic colitis: From bench to bedside.

Microscopic colitis (MC) is a general term that describes a family of chronic inflammatory bowel diseases, including lymphocytic colitis (LC) and collagenous colitis (CC). The two forms are characterized by chronic watery diarrhea with normal or near normal endoscopic colonic appearance and specific histopathological abnormalities.Data from recent epidemiological studies reported the diagnosis ...